[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Greater Atlanta Integrative Pediatrics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":55},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100637682","phase-1-gaip-asd-research-study-100637682",false,"NCT07622316","GAIP ASD Research Study","Greater Atlanta Integrative Pediatrics Autism Spectrum Disorder Research Study","Inclusion Criteria:\n\n* Age 3 years and up\n* Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2 or its equivalent)\n* Parent\u002Fguardian willingness to consider experimental treatments and comply with study requirements\n* Ability to obtain required bloodwork\n* Ability to attend all scheduled visits\n\nExclusion Criteria:\n\n* Severe allergies to study products\n* Significant uncontrolled medical conditions\n* Immunocompromised\n* Malignancy history\n* Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion\n* Pregnancy or breastfeeding (if applicable)\n* Participation in another interventional trial within 30 days","ALL","3 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This clinical research study evaluates the safety and preliminary effects of AdiaVita (umbilical cord blood-derived stem cells and exosomes) combined with glutathione versus glutathione alone in people aged 3 and older with Autism Spectrum Disorder (ASD). In this randomized, participant-blinded crossover trial of about 100 participants, one group receives three monthly AdiaVita IV infusions plus glutathione, while the control group gets placebo saline infusions with the same glutathione regimen; the primary outcome is improvement on Autism Treatment Evaluation Checklist (ATEC) scores, with full safety follow-up through 12 months and optional crossover to AdiaVita for eligible controls. The treatment is investigational and not FDA-approved for autism, with no guaranteed benefit and risks including infusion reactions; participants pay $12,000 for the initial schedule, and all data remains confidential.",[26,27,28,29],"Autism Spectrum Disorder","Autism","ASD","Autism Spectrum Disorder (ASD)",[31,32,33,34,35,36,37,27,26,28,38,39,40,41,42],"Glutathione","Intravenous glutathione","Glutathione therapy","Antioxidant therapy","Oxidative stress","Immune modulation","Anti-inflammatory therapy","Autism symptoms","Stem cell therapy","Regenerative medicine","Allogeneic stem cells","Cellular therapy","RECRUITING","2026-06-01",{"date":46,"type":47},"2026-06-03","ACTUAL",{"date":44,"type":20},{"date":50,"type":20},"2027-06-30",{"name":52,"class":53},"Greater Atlanta Integrative Pediatrics","OTHER",2,""]